Sanofi US Issues Auvi-Q Recall
Auvi-Q Recalled for Potentially Inaccurate Dosage Delivery
Due to potential inaccurate dosage delivery, Sanfi U.S. has issued a nationwide voluntary recall of the epinephrine injection product Auvi-Q.
What caused the recall of Auvi-Q?
The nationwide recall of Auvi-Q came about due to concern that insufficient or inaccurate dosage levels in Auvi-Q could result in ineffective treatment of patients experiencing anaphylaxis.
Anaphylaxis is a potentially life-threatening condition in which the throat swells due to allergic reaction. The swelling of the throat can leave victims of allergic reaction unable to breathe, leading to severe injury or death. Auvi-Q is an epinephrine injection used to alleviate the symptoms the anaphylaxis, reducing swelling in the throat and allowing the patient to breathe. Patients should always seek medical care and attention immediately following an anaphylaxis attack, even when proper dosage of epinephrine injection is administered.
What dosage levels of Auvi-Q have been recalled?
Auvi-Q units containing 0.15 mg and 0.3 mg dosages have been recalled. Units on the market including lot numbers 2081278 through 3037230 (set to expire from October 2015 through December 2016) should be sent back to avoid potential insufficient dosage levels in case of anaphylaxis.
Contact us as soon as possible to receive an alternate epinephrine auto-injector prescription and discuss any issues relating to this recall.
You may also visit Auvi‑Q.com and call 1‑866‑726‑6340 or 1-877-319-8963 Monday through Friday (8 am to 8 pm ET) for assistance on how to return recalled Auvi-Q devices.
talk to a doctor
Fill out the form Below to Request a Consultation.